Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: purified water; croscarmellose sodium; lactose monohydrate; maize starch; copovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; magnesium stearate; microcrystalline cellulose; maize starch; copovidone; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; copovidone; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; maize starch; copovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: copovidone; microcrystalline cellulose; lactose monohydrate; magnesium stearate; croscarmellose sodium; maize starch; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; crospovidone; microcrystalline cellulose; maize starch; povidone; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: crospovidone; povidone; lactose monohydrate; magnesium stearate; microcrystalline cellulose; maize starch; titanium dioxide; hypromellose; macrogol 4000 - treatment of major depression.

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 10 mg - citalopram, is indicated for the treatment of depression. the efficacy of citalopram hydrobromide, in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied. the efficac

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 10 mg - citalopram, is indicated for the treatment of depression. the efficacy of citalopram hydrobromide, in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied. the efficac

United States - English - NLM (National Library of Medicine)

stat rx usa - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram hydrobromide 10 mg - citalopram hbr is indicated for the treatment of depression. the efficacy of citalopram hbr in the treatment of depression was established in 4-6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied. the efficacy of citalop